📊 DRTSW Key Takeaways
Is Alpha Tau Medical Ltd. (DRTSW) a Good Investment?
Alpha Tau Medical Ltd. presents an uninvestable profile due to complete absence of reported financial data across all fundamental metrics. With zero revenue reported, no profitability indicators, and negligible insider activity, there is insufficient evidence of operational viability or financial substance to support any investment thesis.
Alpha Tau Medical is still a pre-revenue, clinical-stage company, so the core fundamental story is balance-sheet durability rather than operating profitability. Full-year 2025 showed widening losses and higher operating cash burn, but the company ended December 31, 2025 with $76.9 million in cash, cash equivalents and deposits and management states that liquidity should cover at least two years of operating and capital needs. The business remains fundamentally speculative until it converts clinical and regulatory progress into recurring revenue.
Why Buy Alpha Tau Medical Ltd. Stock? DRTSW Key Strengths
- No strengths identified
- Strong liquidity position with $76.9 million in cash, cash equivalents, short-term deposits and restricted deposits at December 31, 2025
- Low traditional balance-sheet leverage, with equity of $77.1 million comfortably above long-term loan balances
- Ongoing clinical and regulatory progress, including first marketing approval in Japan and continued U.S. trial expansion, supports growth optionality
DRTSW Stock Risks: Alpha Tau Medical Ltd. Investment Risks
- Complete lack of revenue reporting indicates either pre-revenue status or severe financial reporting deficiencies
- Absence of all balance sheet, cash flow, and profitability metrics prevents fundamental analysis of financial health
- Zero insider Form 4 filings in last 90 days suggests minimal management confidence or activity
- Only 1 metric available indicates severe data gaps in SEC filings or company has not yet filed required financial statements
- Inability to assess liquidity, solvency, or operational efficiency due to missing financial statements
- No revenue to date, meaning the company still lacks proof of commercial demand and operating self-sufficiency
- Losses and cash burn are rising, with net loss increasing to $42.6 million and operating cash outflow to $26.7 million in 2025
- Execution risk remains high because future fundamentals depend on successful trials, regulatory approvals, manufacturing scale-up and commercialization
Key Metrics to Watch
- Quarterly revenue recognition and growth trajectory once financial data becomes available
- Cash burn rate and runway given apparent pre-revenue or non-reporting status
- Balance sheet composition and capital structure once fully disclosed in SEC filings
- Annual operating cash burn relative to cash and deposits
- First meaningful commercial revenue following regulatory approvals and product launches
Alpha Tau Medical Ltd. (DRTSW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
DRTSW Profit Margin, ROE & Profitability Analysis
DRTSW vs Healthcare Sector: How Alpha Tau Medical Ltd. Compares
How Alpha Tau Medical Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Alpha Tau Medical Ltd. Stock Overvalued? DRTSW Valuation Analysis 2026
Based on fundamental analysis, Alpha Tau Medical Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Alpha Tau Medical Ltd. Balance Sheet: DRTSW Debt, Cash & Liquidity
DRTSW Revenue Growth, EPS Growth & YoY Performance
DRTSW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Alpha Tau Medical Ltd. (CIK: 0001871321)
❓ Frequently Asked Questions about DRTSW
What is the AI rating for DRTSW?
Alpha Tau Medical Ltd. (DRTSW) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DRTSW's key strengths?
Claude: . ChatGPT: Strong liquidity position with $76.9 million in cash, cash equivalents, short-term deposits and restricted deposits at December 31, 2025. Low traditional balance-sheet leverage, with equity of $77.1 million comfortably above long-term loan balances.
What are the risks of investing in DRTSW?
Claude: Complete lack of revenue reporting indicates either pre-revenue status or severe financial reporting deficiencies. Absence of all balance sheet, cash flow, and profitability metrics prevents fundamental analysis of financial health. ChatGPT: No revenue to date, meaning the company still lacks proof of commercial demand and operating self-sufficiency. Losses and cash burn are rising, with net loss increasing to $42.6 million and operating cash outflow to $26.7 million in 2025.
What is DRTSW's revenue and growth?
Alpha Tau Medical Ltd. reported revenue of N/A.
Does DRTSW pay dividends?
Alpha Tau Medical Ltd. does not currently pay dividends.
Where can I find DRTSW SEC filings?
Official SEC filings for Alpha Tau Medical Ltd. (CIK: 0001871321) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DRTSW's EPS?
Alpha Tau Medical Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DRTSW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Alpha Tau Medical Ltd. has a SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DRTSW stock overvalued or undervalued?
Valuation metrics for DRTSW: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DRTSW stock in 2026?
Our dual AI analysis gives Alpha Tau Medical Ltd. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DRTSW's free cash flow?
Alpha Tau Medical Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does DRTSW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).